HK1223852A1 - 睪丸酮凝膠組合物及相關方法 - Google Patents

睪丸酮凝膠組合物及相關方法

Info

Publication number
HK1223852A1
HK1223852A1 HK16112308.4A HK16112308A HK1223852A1 HK 1223852 A1 HK1223852 A1 HK 1223852A1 HK 16112308 A HK16112308 A HK 16112308A HK 1223852 A1 HK1223852 A1 HK 1223852A1
Authority
HK
Hong Kong
Prior art keywords
related methods
gel compositions
testosterone gel
testosterone
compositions
Prior art date
Application number
HK16112308.4A
Other languages
English (en)
Inventor
Harish K Pimplaskar
Original Assignee
Upsher-Smith Laboratories Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upsher-Smith Laboratories Llc filed Critical Upsher-Smith Laboratories Llc
Publication of HK1223852A1 publication Critical patent/HK1223852A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16112308.4A 2013-12-13 2016-10-26 睪丸酮凝膠組合物及相關方法 HK1223852A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915742P 2013-12-13 2013-12-13
US14/177,765 US8785426B1 (en) 2013-12-13 2014-02-11 Testosterone gel compositions and related methods
PCT/US2014/069760 WO2015089289A1 (en) 2013-12-13 2014-12-11 Testosterone gel compositions and related methods

Publications (1)

Publication Number Publication Date
HK1223852A1 true HK1223852A1 (zh) 2017-08-11

Family

ID=51177812

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16112308.4A HK1223852A1 (zh) 2013-12-13 2016-10-26 睪丸酮凝膠組合物及相關方法

Country Status (8)

Country Link
US (3) US8785426B1 (zh)
EP (1) EP3079703A4 (zh)
AU (1) AU2014362275A1 (zh)
CA (1) CA2857286C (zh)
HK (1) HK1223852A1 (zh)
SG (1) SG11201604788UA (zh)
WO (1) WO2015089289A1 (zh)
ZA (1) ZA201604587B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2699674C1 (ru) * 2015-09-30 2019-09-09 Фуджифилм Корпорэйшн Композиция для чрескожной абсорбции
WO2020069450A1 (en) * 2018-09-28 2020-04-02 Joel Studin Transpore delivery of drugs and uses thereof
BE1030538B1 (nl) * 2022-05-18 2023-12-19 Bogaert Gina Van Liposomaal preparaat met ingekapselde hormonen, werkwijze voor de productie en gebruik ervan

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US5332577A (en) 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
DE69326461T2 (de) 1992-06-11 2000-05-04 Theratech Inc Verwendung von glyzerin zur dämpfung der transdermalen arzneimittelverabreichung
US6010691A (en) 1993-03-19 2000-01-04 The Regents Of The University Of California Methods for enhancing permeation of a topically administered physiologically active substance
US5760096A (en) 1996-10-18 1998-06-02 Thornfeldt; Carl R. Potent penetration enhancers
US6019997A (en) 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
US5908619A (en) 1997-01-09 1999-06-01 Minnesota Mining And Manufacturing Company Hydroalcoholic compositions thickened using surfactant/polymer complexes
IL136042A (en) 1997-11-10 2005-12-18 Cellegy Pharma Inc Alcohol-containing composition for topical application
WO1999032153A1 (en) 1997-12-22 1999-07-01 Alza Corporation Monoglyceride and ethyl palmitate permeation enhancer compositions
PL192270B1 (pl) 1998-03-19 2006-09-29 Merck & Co Inc Ciekła kompozycja polimeryczna do kontrolowanego uwalniania eprinomektyny
ES2359973T3 (es) 1998-03-19 2011-05-30 MERCK SHARP & DOHME CORP. Composiciones poliméricas líquidas para la liberación controlada de sustancias bioactivas.
WO2002011768A1 (en) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
WO2002017927A1 (en) 2000-08-30 2002-03-07 Unimed Pharmaceuticals, Inc. Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
CA2451839C (en) 2001-06-22 2013-08-06 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions comprising peptides and permeation enhancers
JP3909812B2 (ja) 2001-07-19 2007-04-25 富士フイルム株式会社 表示素子及び露光素子
AU2002340120A1 (en) 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
FR2832311B1 (fr) 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
MY139721A (en) 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
NZ537360A (en) 2002-06-25 2006-09-29 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
FR2851470B1 (fr) 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
AU2004251731A1 (en) 2003-06-23 2005-01-06 Macrochem Corporation Compositons and methods for topical administration
MXPA06000474A (es) 2003-07-11 2007-06-05 Macrochem Corp Composiciones farmaceuticas para aplicaciones topicas.
DK1937276T3 (da) 2005-10-12 2013-02-11 Besins Healthcare Luxembourg Forbedret testosterongel og fremgangsmåde til anvendelse deraf
US20120022033A1 (en) * 2010-07-23 2012-01-26 Biosante Pharmaceuticals, Inc. Methods for decreasing cardiovascular risk in postmenopausal women
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013130535A1 (en) 2012-02-27 2013-09-06 Newgen Biopharma Corporation Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same

Also Published As

Publication number Publication date
US8785426B1 (en) 2014-07-22
EP3079703A4 (en) 2017-07-12
ZA201604587B (en) 2017-11-29
US20150164913A1 (en) 2015-06-18
US20160310508A1 (en) 2016-10-27
US9662340B2 (en) 2017-05-30
CA2857286A1 (en) 2014-11-21
AU2014362275A1 (en) 2016-07-21
SG11201604788UA (en) 2016-07-28
WO2015089289A1 (en) 2015-06-18
CA2857286C (en) 2016-01-12
EP3079703A1 (en) 2016-10-19
US9295675B2 (en) 2016-03-29

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
HK1218837A1 (zh) 組合物和方法
HK1218560A1 (zh) 組成與方法
GB2533892B (en) Compositions and methods
IL286759A (en) Therapeutic methods and preparations
IL265876A (en) Preparations that include 15-ohepa and methods of using them
GB201308072D0 (en) Compositions and methods
EP2968474A4 (en) SKIN COMPOSITIONS AND USES
GB201305813D0 (en) Compositions and methods
EP3065829A4 (en) Compositions and methods for treating melanoma
IL240090A0 (en) Preparations containing l-4-chloroquinonerine
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
HK1223852A1 (zh) 睪丸酮凝膠組合物及相關方法
HK1222560A1 (zh) 抗流感組合物和方法
IL246134A0 (en) Gel preparations containing testosterone and their uses
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods
EP3003323A4 (en) POLYSACCARIDE COMPOSITIONS AND CORRESPONDING METHODS
AU2013902874A0 (en) Compositions and methods
GB201319255D0 (en) Therapeutic compositions and methods
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same
GB201319917D0 (en) Accelerator Compositions and Methods
GB201308242D0 (en) Compositions and uses thereof